Security

Vertex Pharmaceuticals (VRTX) Research Hub

Finvaulta tracks 6 research reports on VRTX, updated through September 6, 2026. Latest: Back-to-School Kickstart: 10 High-Level Themes; Selectively Constructive.

Institutional research on VRTX covering equities, commodities, macro, and government bonds, from Goldman Sachs. Finvaulta indexes each report with a summary, key figures and its original publication date.

Finvaulta is an independent research collection; views and forecasts belong to the named report issuers.

Latest research

Back-to-School Kickstart: 10 High-Level Themes; Selectively Constructive

Goldman Sachs·Sep 6, 2026

Goldman Sachs remains selectively constructive on large-cap biopharma entering fall 2026, supported by ~18% YTD outperformance, positive earnings revisions, and innovation in cancer vaccines. Key favored names into year-end include JNJ, LLY, AMGN, RPRX, MRK, TEVA, VRTX, AZN, and Bayer, while Novartis, BMY, and PFE face higher-risk catalyst paths.

Midday Market Intelligence: Sentiment Shift?

Goldman Sachs·Sep 1, 2026

US stocks traded lower on September 1, 2026, as investors evaluated a decline in the ISM Manufacturing Index to 54.6 and climbing 10-year Treasury yields at pre-GFC levels. Goldman Sachs maintained its 3Q26 GDP tracker at +2.7% and added Vertex Pharmaceuticals (VRTX, $653 PT) to its US Conviction List.

Americas Healthcare Biotechnology Script Tracker

Goldman Sachs·Jul 6, 2026

This report provides a weekly script data tracker for major biotechnology launches including ALNY's Amvuttra, BIIB's Leqembi, and VRTX's Journavx. Analysts provide insights on sales trajectories and monitoring metrics for upcoming quarters.

Americas Healthcare Biotechnology Script Tracker

Goldman Sachs·Jun 12, 2026

This report tracks weekly prescription trends for key biotech products including Amvuttra, Leqembi, Yeztugo, Journavx, Spikevax, and Uplizna. Data is provided as an aid to assessing 2Q sales tracking against consensus expectations.

Vertex Pharmaceuticals Inc. Key Takeaways

Goldman Sachs·Jun 10, 2026

This report summarizes key takeaways from Vertex Pharmaceuticals' presentation at the 47th Annual Global Healthcare Conference, focusing on the company's progress in cystic fibrosis, kidney disease therapies, and upcoming pipeline catalysts.

Healthcare Biotechnology Script Tracker

Goldman Sachs·May 8, 2026

This Goldman Sachs report tracks weekly script data for key biotechnology launches including Amvuttra, Leqembi, Yeztugo, and Journavx. It provides Wo-W performance metrics and management outlooks for US commercial execution through 2026-2027.